Top Message
The Kyorin Group is working to realize the corporate philosophy “Kyorin continues to fulfill its mission of cherishing life, and benefiting society by contributing to better health“.
Based on its corporate philosophy “to cherish life and benefit society by contributing to better health,” the Group have decided to formulate a new long-term vision “Vision 110” and aim to become “a company that contributes broadly to people's health by comprehensively developing healthcare-related businesses, with a core focus on the new drug business, which continuously provides high-value new drugs that meet medical needs”.
While there are various social issues to be solved, the sustainable growth of a company (economic value) and the realization of a sustainable society through business activities (social value) are becoming more and more important. The Group develops and provides useful and safe products and services by developing a combination of the ethical drug business and the healthcare business, which are our core businesses and we will contribute to sustainable economy growth and resolution of social issues. We will also work to strengthen corporate governance in order to carry out sustainable business activities.
As part of this, we revised the Corporate Behavior Charter and Compliance Guidelines in April 2019 to further penetrate the company.
The Kyorin Group hopes to be a company that continuously contributes to the sustainable development of society and is recognized by society while communicating with stakeholders.
Your Health is Kyorin’s Mission.
KYORIN Pharmaceutical Co., Ltd.
Representative Director, President and Chief Executive Officer
Yutaka Ogihara
Basic policy on sustainability
Following our corporate philosophy, “Kyorin continues to fulfill its mission of cherishing life and benefiting society by contributing to better health,” the Kyorin group is proactively addressing sustainability issues for society’s continuous development through business activities based on our Corporate Charter, as we work to enhance corporate value over the medium to long term..
Designation of materiality
Using a matrix with one axis representing social importance and the other axis standing for importance to the Group, we have designated 10 items as materiality from among the various issues related to sustainability. We will place a priority on addressing these issues from the perspective of “value creation (issues directly connected to business activities)” and the perspective of a “base to support value creation (issues related to a base for business activities)” as we work to achieve the goals of the long-term vision “Vision 110.”
Corporate philosophy
Long-term vision
Vision 110
Materialities
(Important issues)
Medium-term business plan
Vision 110 –Stage1–
Policies and plans for each fiscal year
Designation of important issues referencing social concerns
Value creation
materiality
- Creating high-value products that meet medical needs
- Maximizing value of products
- Providing a stable supply of high-quality pharmaceutical products
Base to support value creation
materiality
- Enhancing human capital
- Promoting work-style reforms that respect diverse values
- Promoting health management
- Carrying out environmentally friendly business activities
- Ensuring thorough compliance
- Strengthening corporate governance
- Strengthening relationships with stakeholders
Process for designation materiality
Materiality is designated by the following process, based on the Kyorin Group’s forward-looking environment outlook and analysis and referral to various principles and guidelines.
These issues are continuously reviewed in light of environmental changes, the Kyorin Group’s business activities and demand of society.
-
1. Identification of issuesIssue are identified based on various principles and guidelines (including ISO 26000, the UN’s Sustainable Development Goals, and the materiality map for the healthcare industry formulated by the Sustainability Accounting Standards Boards,
-
2. Narrowing drown issuesIdentified issues are narrowed down in light of the Group’s corporate philosophy, long-term vision, etc.
-
3. Assignment of priorityIssues of particularly high priority and identified using a matrix with two axes-importance to society and importance to the Group.
-
4. Designation of materialityIssue identified as important for materiality are deliberated by the Management Committee and resolved by the Board of Directors.
Materiality
Corporate philosophy
Value creation
| Materiality | KPI | Related SDGs |
|---|---|---|
|
|
|
|
|
|
|
|
Base to support value creation
| Materiality | KPI | Related SDGs |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate Charter
- 1Contribute to sustainable economic growth and to the resolution of social issues
- 2Rigorous and scientific research and development
- 3Promotion of appropriate use of drugs
- 4Relationships of trust with medical professionals, patients, etc.
- 5Fair business practices
- 6Thorough information management
- 7Fair information disclosure and constructive dialogue with stakeholders
- 8Work-style reforms and improvement of work environments
- 9Initiatives to tackle environmental issues
- 10Co-exist with society and contribute to society’s development
- 11Comprehensive crisis management
- 12Respect for human rights
- 13Stringent implementation by Company officers of their responsibilities and the charter
Relationships with stakeholders
SDGs (Sustainable Development Goals)
The SDGs are a series of international goals targeted for achievement by 2030 adopted at the 2015 United Nations Summit. The Kyorin Group has incorporated these goals into its business practices and eff orts to co-exist with society, and works to contribute to the realization of a sustainable society.
